Action Churchill Capital Corpor... - CCXI

Churchill Capital Corporation XI (CCXI) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

10,305

( - )

Prix Achat

10,25

Prix Vente

10,35

Volume échangé

0,00 Fourchette du Jour 0,00

10,0946 Plage de 52 semaines 51,99

Cap du marché

573,989M

Clôture Veille

10,305

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

US$ 27 288

Actions en circulation

55 700 000

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

Bénéfice par action (BPA)

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

655,03k

Churchill Capital Corp XI does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2025 and is based in New York, ... Churchill Capital Corp XI does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2025 and is based in New York, New York. Show more

Secteur

Industrie

Site Web

churchillcapital-11.com

Siège social

New York, United States

Fondé

2026

Churchill Capital Corporation XI est coté dans le secteur de la NASDAQ avec le ticker CCXI. Le dernier cours de clôture d'Churchill Capital Corpor... était de US$10,31. Au cours de la dernière année, les actions de Churchill Capital Corpor... ont été négociées dans une fourchette de prix de US$ 10,0946 à US$ 51,99.

Churchill Capital Corpor... compte actuellement 55 700 000 actions en circulation. La capitalisation boursière d'Churchill Capital Corpor... est de US$573,99 million.

Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026

New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Churchill Capital Corp XI (Nasdaq: CCXIU) (the “Company”) announced today that, commencing...

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire THOUSAND OAKS, Calif., Oct. 20, 2022...

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of...

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in...

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced...

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the...

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH PR Newswire THOUSAND OAKS, Calif. and SAN CARLOS, Calif...

ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced...

ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced...

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.105	1.02941176471	10.2	11.125	10.2	6794	10.30320492	CS
4	0.105	1.02941176471	10.2	11.125	10.2	23945	10.22575418	CS
12	0.195	1.92878338279	10.11	11.125	10.11	20629	10.21726563	CS
26	-41.685	-80.178880554	51.99	51.99	10.0946	13105	10.20025781	CS
52	-41.685	-80.178880554	51.99	51.99	10.0946	6448	10.20025781	CS
156	-41.685	-80.178880554	51.99	51.99	10.0946	2144	10.20025781	CS
260	-2.705	-20.7916986933	13.01	52	10.0946	636275	32.20599285	CS

CCXI - Frequently Asked Questions (FAQ)

What is the current Churchill Capital Corporation XI share price?

The current share price of Churchill Capital Corporation XI is US$ 10,305

How many Churchill Capital Corporation XI shares are in issue?

Churchill Capital Corporation XI has 55 700 000 shares in issue

What is the market cap of Churchill Capital Corporation XI?

The market capitalisation of Churchill Capital Corporation XI is USD 573,99M

What is the 1 year trading range for Churchill Capital Corporation XI share price?

Churchill Capital Corporation XI has traded in the range of US$ 10,0946 to US$ 51,99 during the past year

What is the registered address of Churchill Capital Corporation XI?

The registered address for Churchill Capital Corporation XI is 640 Fifth Avenue, New York, New York, 10019

What is the Churchill Capital Corporation XI website address?

The website address for Churchill Capital Corporation XI is churchillcapital-11.com

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Churchill Capital Corporation XI (CCXI)

Churchill Capital Corporation XI (CCXI) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Churchill Capital Corporation XI

CCXI Dernières nouvelles

Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026

CCXI - Frequently Asked Questions (FAQ)

CCXI Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Churchill Capital Corporation XI (CCXI)

Churchill Capital Corporation XI (CCXI) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Churchill Capital Corporation XI

CCXI Dernières nouvelles

Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026

CCXI - Frequently Asked Questions (FAQ)

CCXI Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités